ClinicalTrials.gg
TerminatedNCT04137159Updated Nov 17, 2026Results posted

An Exercise Intervention to Reduce Neuropathic Pain and Brain Inflammation After Spinal Cord Injury

An interventional study of Functional Electrical Stimulation rowing exercise in Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Basic science

How we know

Why this study was terminated
Lack of recruitment
Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital — 3 open to participants now, 8 under way, none of them phase 3. Spinal Cord Injuries · Spaulding Rehabilitation Hospital.

Enrollment
19th of 25
13 · median 24
Started
2020
with 2 others
No phase
21 of 25
3 open now
Registered
15th of 25
by date

Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, this one is the 19th largest by enrollment, is one of 3 that started in 2020, is one of 21 with no phase, and was the 15th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, or all of them as a file.
02

Study summary

Spinal Cord Injury (SCI) leads to alterations in brain structure and function by spinal nerve damage, secondary inflammatory responses, and by the consequences of living with paralysis and neuropathic pain. Physical inactivity due to lower body paralysis rapidly leads to loss of muscle, and risk of heart disease. The leading cause of death after a spinal cord injury is cardiovascular disease, and just a year after injury, those with SCI have a peak exercise capacity half that of the unfit general population.

The good news is that aerobic exercise reduces the risk of chronic metabolic and cardiorespiratory diseases, reduces inflammation and pain, and increases mood and quality of life. Exercise can also reduce brain inflammation, enhance endogenous analgesia, and increases the size of the hippocampus.

The issue is that muscle paralysis in SCI restricts the ability to achieve the levels of exercise that is necessary for broad analgesic, anti-inflammatory and neuroprotective benefits. Arm exercise can have some effects on heart and lung capacity, but the small muscle mass is insufficient to produce more than modest aerobic work. With functional electrical stimulation (FES), leg muscles that are paralyzed can be made to contract, thereby allowing more of the body to be exercised. The full rowing stroke is produced by both the (stimulated) legs and arms, increasing the active muscle mass and resulting in an aerobic work-out that is intensive enough to improve heart, lung, and - maybe - brain function.

In this clinical trial of sub-acute spinal cord injured subjects, the investigators will study how 12 weeks of FES-RT, in comparisons to 12 weeks of wait-list, changes pain, brain structure, endogenous opioid function and brain inflammation.

The investigators will measure changes using positron emission tomography and magnetic resonance imaging. The investigators hypothesize a decrease in pain interference, an increase in hippocampal volume, increased endogenous opioid transmission in the periaqueductal gray, and decreased hippocampus neuroinflammation.

Read the detailed description

This clinical trial will utilize a randomized, controlled, crossover design. Participants will be randomized to (A) 12 weeks of FES-RT followed by 12 weeks of treatment as usual or (B) 12 weeks of treatment as usual followed by 12 weeks of FES-RT.

Randomization will be computer generated and the study statistician will keep the key to appropriately conceal allocation of treatment until after obtaining baseline measures.

Exercise Intervention:

FES-RT occurs in two distinct steps - an initial strength training step, followed by FES-RT. Those with SCI can require at least two weeks and up to six weeks of strength-training. For the strength training, electrodes are placed over motor points of the quadriceps and hamstrings and intensity of the stimulus is set at the level producing full knee flexion-extension. Training is performed until subjects can complete a flexion extension protocol for 30 min without rest. During this time, the first set of PET-MR data will be obtained.

Subsequently, the FES-RT commences.

Measurements / Assessments Exercise Capacity: Volunteers will perform an incremental exercise test of FES- or arms-only rowing to determine maximal oxygen uptake on a day normally scheduled for regular exercise training. Exercise capacity and aerobic power will be determined from on-line computer-assisted open circuit spirometry. Subjects will row with increasing resistance every 2 min until volitional fatigue. To ensure attainment of maximal exercise capacity, at least 3 of these criteria will be met: 1) O2 consumption plateaus despite increasing workload, 2) respiratory exchange ratio >1.10 at end exercise, 3) age-predicted maximal heart rate is achieved, and 4) perceived exertion is rated at least 16 on the Borg scale of 6-20.

Exercise Volume: The progression of the exercise stimulus across the training program will be assessed from duration, frequency, and intensity derived from heart rate monitored during each exercise bout (i.e., Training Impulses or TRIMPs) as well as the product of average wattage and total duration for each week. TRIMPs are routinely used to quantify the exercise load and is specific to the cardiopulmonary system. The investigators will also calculate exercise load or work as the product of the weekly average of wattage and weekly total of exercise time.

PET-MR imaging

Neuroimaging metrics will be obtained at baseline, after 12 weeks and after 24 weeks. MR-PET scanning will be performed at 3 Tesla, using a Siemens whole-body MRI, whole-body PET camera (Biograph MMR). MRI data will be acquired simultaneously to the PET data.

In response to injury, microglia migrate to the site of injury, and express multiple cell surface proteins, including the translocator protein (18kDa) (TSPO). This conditional expression makes TSPO a prime target for PET imaging (127). There are multiple candidate PET tracers for glial activity , whereof 11C-PBR28 is a sensitive, second generation, high affinity TSPO radioligand suitable for imaging of microglial and astrocytic activation in neuroinflammation in humans. For glial imaging, 11C-PBR28 will be injected intravenously with a slow bolus over a 30s period (130). Dynamic data will be collected over the brain for 90 minutes in list mode, and framed post-collection. The dose will be up to 15mCi, which is equivalent to \~3.7 mSv.

For opioid imaging, 11C-diprenorphine will be injected intravenously, Dynamic data will be collected over the brain for 90 minutes in list mode, and framed post-collection. The dose will be up to 12mCi, which is equivalent to \~2.5 mSv.

For both scans, MR-based attenuation correction maps are created based on the MPRAGE data. For glial imaging, standardized uptake values (SUV), normalized to whole brain PBR28 ligand uptake, will be used. For 11CDiprenorphine, kinetic modeling is carried our using subject specific bilateral occipital cortices as the reference tissues. Nondisplaceable binding potential maps (BPND), representing the relative amount of specifically bound radioligand to that of non-displaceable radioligand, are calculated from the 90 min of dynamic PET data using a simplified reference tissue model with the occipital cortex used as the reference tissue.

A high resolution structural volume will be collected for the purposes of longitudinal structural analyses. All longitudinal data analyses will be done in native space as repeated measurements, thereby avoiding spatial normalization errors typically associated with cohort studies.

A battery of pain, quality of life and psychological well-being questionnaires to the participants on four occasions: immediately after enrollment, at the start of the 12 week wait-list or FES-RT period, at the end of the first arm, and at the end of the cross-over arm (24 weeks).

Conditioned pain modulation: Conditioned pain modulation (CPM) is a psychophysically-based laboratory method to reliably ) evaluate the individual capabilities to inhibit pain in humans. Briefly, CPM is based on the "pain inhibits pain" phenomenon when Stimulus A (test-pain) given together with Stimulus B (conditioning pain) is perceived less painful than when Stimulus A was given alone. Although the literature is not entirely consistent, CPM can be reduced with naltrexone, suggesting at least partial dependence of inhibition on endogenous opioids. CPM will be determined at baseline, 12 weeks and 24 weeks, with the hypothesis that FES-RT will lead to increased CPM.

03

Conditions studied

  • Spinal Cord Injuries
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

* SCI at or below neurological level C5 with American Spinal Injury Association grade A, B or C, within 3-24 months after injury.

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • breast feeding
  • to MRI
  • contraindications to PET current or past history of:
  • major medical illness
  • major neurological illness other than SCI
  • major psychiatric illness
  • diabetes
  • major kidney or liver problems
  • use of tobacco
  • use of recreational drugs
  • an abnormal physical exam (e.g., heart murmurs or peripheral edema).
  • unresponsive to FES stimulation
  • heart disease
  • physical limitations to FES-RT success
  • blood pressure>140/90 mmHg
  • significant arrhythmias
  • cancer
  • epilepsy
  • current use of cardioactive medications
  • current grade 2 or greater pressure injuries at relevant contact sites
  • peripheral nerve compressions or rotator cuff tears that limit the ability to row
  • history of bleeding disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    FES rowing

    Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.

    Other: Functional Electrical Stimulation rowing exercise

  • No intervention
    Wait list

    During the 12-week treatment as usual program, subjects will not participate in FES-rowing.

Interventions

  • OtherFunctional Electrical Stimulation rowing exercise

    Full-body aerobic exercise

06

What researchers measure

Primary outcomes

  1. Change in PROMIS Pain Interference Questionnaire VAS Pain

    The Patient-Reported Outcomes Measurement Information System (PROMIS(r)) Pain Interference instrument measure the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. The scale ranges from 6 to 30, with 30 being the highest pain interference.

    Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list

  2. Change in Hippocampal Volume

    MRI derived measurement of hippocampus volume in milliliters

    Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list

  3. Change in Hippocampus Glial Activation

    11C-PBR28 SUV uptake in the hippocampus

    Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list

  4. Change in PAG Diprenophine Signal

    Diprenorphine binds to mu, kappa, and delta receptors. Because opioid receptors are distributed globally throughout the brain, there is no true biological reference region completely devoid of receptors, see PMID: 8051944 for details. Because spinal cord injured patients commonly experience orthostatic hypotension, arterial blood sampling was not done for safey reasons. As a metric of potential within-subject change in opioid receptor binding potential, we caluclated strandardized uptake values (SUV) in the periaqueductal gray as (tissue radioactivity concentration)/(injected dose/patient weigh). This is a unitless metric that reflects a mix of specific binding to opioid receptors (μ, κ, and δ), non-specific tissue binding and free tracer in tissue. A change in Diprenoprhine SUV signal in the PAG is likely to represent, in part, a within-subject change in opoid binding potential. For a detailed discussion, please see PMID: 15275909

    Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneFES RowingWait List
Started85
Completed31
Not completed54
Withdrew: Withdrawal by subject32
Withdrew: Technical difficultis with pet/mr22

Outcome measures

PrimaryChange in PROMIS Pain Interference Questionnaire VAS Pain

The Patient-Reported Outcomes Measurement Information System (PROMIS(r)) Pain Interference instrument measure the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. The scale ranges from 6 to 30, with 30 being the highest pain interference.

Time frame:
Change between baseline and after 12 week FES intervention, and after 12 week wait list
Reported as:
Mean · units on a scale
Change in PROMIS Pain Interference Questionnaire VAS Pain
units on a scaleFES RowingWait List
Change in PROMIS Pain Interference Questionnaire VAS Pain1.9 ± 2.12.3 ± 2.6
PrimaryChange in Hippocampal Volume

MRI derived measurement of hippocampus volume in milliliters

Time frame:
Change between baseline and after 12 week FES intervention, and after 12 week wait list
Reported as:
Mean · ml
Change in Hippocampal Volume
mlFES RowingWait List
Change in Hippocampal Volume-0.007 ± 0.0960.079 ± 0.096
PrimaryChange in Hippocampus Glial Activation

11C-PBR28 SUV uptake in the hippocampus

Time frame:
Change between baseline and after 12 week FES intervention, and after 12 week wait list
Reported as:
Mean · Standardized Uptake Value
Change in Hippocampus Glial Activation
Standardized Uptake ValueFES RowingWait List
Change in Hippocampus Glial Activation0.07366122 ± 0.0970930.00872274 ± na
PrimaryChange in PAG Diprenophine Signal

Diprenorphine binds to mu, kappa, and delta receptors. Because opioid receptors are distributed globally throughout the brain, there is no true biological reference region completely devoid of receptors, see PMID: 8051944 for details. Because spinal cord injured patients commonly experience orthostatic hypotension, arterial blood sampling was not done for safey reasons. As a metric of potential within-subject change in opioid receptor binding potential, we caluclated strandardized uptake values (SUV) in the periaqueductal gray as (tissue radioactivity concentration)/(injected dose/patient weigh). This is a unitless metric that reflects a mix of specific binding to opioid receptors (μ, κ, and δ), non-specific tissue binding and free tracer in tissue. A change in Diprenoprhine SUV signal in the PAG is likely to represent, in part, a within-subject change in opoid binding potential. For a detailed discussion, please see PMID: 15275909

Time frame:
Change between baseline and after 12 week FES intervention, and after 12 week wait list
Reported as:
Mean · Standardized Uptake Value
Change in PAG Diprenophine Signal
Standardized Uptake ValueFES RowingWait List
Change in PAG Diprenophine Signal-0.065 ± 0.890.069 ± 1.358

Adverse events

Collected over From enrollment until study completion, an average of 1 year per participant. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FES Rowing0/8 (0%)0/8 (0%)0/8 (0%)
Wait List0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FES RowingWait ListTotal
<=18 years000
Between 18 and 65 years8513
>=65 years000
Age, Continuous
Age, Continuous(years)FES RowingWait ListTotal
Mean46 ± 1436 ± 943 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)FES RowingWait ListTotal
Female011
Male8412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FES RowingWait ListTotal
Hispanic or Latino101
Not Hispanic or Latino7411
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FES RowingWait ListTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White7310
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)FES RowingWait ListTotal
United States8513
08

Study locations

1 site
  • Spaulding Rehabilitation Hospital
    Boston, Massachusetts 02129, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No HIPAA protects data will be shared. Neuroimaging data may be shared.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Nov 2024, 56 months.

Results were first posted in Nov 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2019
First posted
Oct 23, 2019
StartActual
Feb 20, 2020
Primary completionActual
Nov 1, 2024
CompletionActual
Nov 1, 2024
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedChange in PROMIS Pain Interference questionnaireQuestionnaire VAS PainTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
  • EditedChange in Hippocampal volumeVolumeTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
  • EditedChange in Hippocampus glial activationGlial ActivationTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
  • ChangedBefore Change PAG opioid binding potentialNow Change in PAG Diprenophine SignalTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
Nov 17, 2026
Documents
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedChange in PROMIS Pain Interference questionnaireQuestionnaire VAS PainTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
    • EditedChange in Hippocampal volumeVolumeTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
    • EditedChange in Hippocampus glial activationGlial ActivationTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
    • ChangedBefore Change PAG opioid binding potentialNow Change in PAG Diprenophine SignalTime frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
    + 3 other changes: verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04137159
Responsible party
Nils Clas Linnman (Assistant Professor, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Oct 23, 2019
Start date
Feb 20, 2020
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Nils C Linnman, PhD
principal investigator · Spaulding Rehabilitation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion